FDA Needs More Time to Review BioCryst's Pediatric HAE Treatment

Rhea-AI Filing Summary

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that the FDA has extended the PDUFA goal date for their NDA regarding ORLADEYO oral granules for pediatric HAE patients aged 2-11 years. The 3-month extension moves the target action date to December 12, 2025. The extension was triggered by the company's submission of additional final reports and formulation data, which the FDA classified as a major amendment requiring full review.

The delay affects the potential expansion of ORLADEYO, currently approved for other age groups, into the pediatric hereditary angioedema market segment. The FDA requires additional time to review the supplementary data for safety and efficacy in young patients.

Positive

• Continued progress in expanding ORLADEYO to pediatric patients
• FDA engagement maintains active review status rather than rejection
• Company demonstrated proactive submission of additional supportive data

Negative

• 3-month delay in potential pediatric market entry
• Additional regulatory uncertainty introduced by extended review period
• Timeline extension may impact commercial planning and market expectations

Insights

Regulatory Affairs Specialist

FDA extension suggests complex data submission requiring thorough safety review for vulnerable pediatric population

The FDA's decision to extend the review period is a standard regulatory procedure when significant new data is submitted late in the review cycle. The classification as a 'major amendment' indicates substantial new information that could materially impact the benefit-risk assessment for pediatric patients. While extensions can be viewed as procedural setbacks, they often result in more thorough evaluations, particularly crucial for pediatric indications where safety standards are exceptionally high. The company's submission of additional formulation data suggests proactive engagement with regulatory requirements, though timing of the submission could have been better planned to avoid delays.

Clinical Development Analyst

Pediatric HAE treatment expansion faces strategic delay but maintains development momentum

The extension for ORLADEYO's pediatric indication represents a calculated development approach in the rare disease space. The focus on ages 2-11 years demonstrates strategic expansion from existing approvals, targeting an underserved patient population. The submission of additional formulation data suggests careful attention to age-appropriate drug delivery, crucial for pediatric compliance. While the timeline shift affects near-term commercialization plans, the continued regulatory progression maintains development momentum in the competitive HAE market.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0000882796 0000882796 2025-06-23 2025-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23186	62-1413174
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant’s telephone number, including area code)

________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

On June 23, 2025, the U.S. Food and Drug Administration (“FDA”) notified BioCryst Pharmaceuticals, Inc. (the “Company”) that it has extended the Prescription Drug User Fee Act (“PDUFA”) goal date for the Company’s new drug application (“NDA”) for the use of once-daily ORLADEYO^® (berotralstat) oral granules in pediatric patients with hereditary angioedema (“HAE”) aged 2 to 11 years. The FDA determined that the Company’s submission of additional final reports and formulation data constituted a major amendment to the NDA, resulting in a standard three-month extension to the original goal date to provide time for a full review of the submission. The new PDUFA target action date is December 12, 2025.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including statements relating to ORLADEYO. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the Company’s ability to successfully progress its development plans, including meeting expected timelines; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; and the FDA or other applicable regulatory agency may not approve ORLADEYO for use in pediatric patients with HAE aged 2 to 11 years within the timeframe expected, or at all, may ultimately determine that there are deficiencies in the development program or execution thereof, may require additional information or studies, may disagree with our safety and efficacy conclusions, may impose certain restrictions, warnings, or other requirements, may impose a clinical hold, or may withhold, delay, or withdraw market approval. Please refer to the documents the Company files periodically with the Securities and Exchange Commission, specifically the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in the Company’s forward-looking statements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 25, 2025	BioCryst Pharmaceuticals, Inc.
	By:	/s/ Alane Barnes
		Alane Barnes
		Chief Legal Officer

FAQ

What is the new PDUFA date for BCRX's ORLADEYO pediatric indication?

The new PDUFA target action date is December 12, 2025, following a three-month extension from the original date.

Why did the FDA extend BCRX's ORLADEYO review period?

The FDA extended the review period because BioCryst submitted additional final reports and formulation data that constituted a major amendment to the NDA, requiring more time for complete review.

What age group is BCRX targeting with this ORLADEYO application?

The NDA is for the use of once-daily ORLADEYO oral granules in pediatric patients with hereditary angioedema (HAE) aged 2 to 11 years.

What type of product formulation is BCRX seeking approval for?

BCRX is seeking approval for ORLADEYO oral granules, a formulation specifically designed for pediatric patients.